NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis $3.56 +0.16 (+4.71%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.64 +0.08 (+2.25%) As of 05/2/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About CureVac Stock (NASDAQ:CVAC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CureVac alerts:Sign Up Key Stats Today's Range$3.54▼$3.7950-Day Range$2.59▼$3.5652-Week Range$2.37▼$5.28Volume679,873 shsAverage Volume797,524 shsMarket Capitalization$798.64 millionP/E Ratio6.47Dividend YieldN/APrice Target$14.00Consensus RatingBuy Company OverviewCureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Read More… CureVac Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreCVAC MarketRank™: CureVac scored higher than 77% of companies evaluated by MarketBeat, and ranked 277th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCureVac has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCureVac has only been the subject of 2 research reports in the past 90 days.Read more about CureVac's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CureVac is 6.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.97.Price to Earnings Ratio vs. SectorThe P/E ratio of CureVac is 6.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.79.Price to Book Value per Share RatioCureVac has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CureVac's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.11% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in CureVac has recently decreased by 1.03%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-2.10 Percentage of Shares Shorted5.11% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in CureVac has recently decreased by 1.03%, indicating that investor sentiment is improving. News and Social Media1.8 / 5News Sentiment0.30 News SentimentCureVac has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for CureVac this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for CVAC on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added CureVac to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.15% of the stock of CureVac is held by insiders.Percentage Held by InstitutionsOnly 17.26% of the stock of CureVac is held by institutions.Read more about CureVac's insider trading history. Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Email Address CVAC Stock News HeadlinesCureVac (NASDAQ:CVAC) Shares Gap Up - Here's What HappenedMay 4 at 2:49 AM | americanbankingnews.comCureVac (NASDAQ:CVAC) Price Target Cut to $12.00 by Analysts at UBS GroupMay 2 at 2:49 AM | americanbankingnews.comBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.May 4, 2025 | Golden Portfolio (Ad)CureVac (CVAC) Target Price Reduced by UBS Analyst | CVAC Stock NewsApril 30, 2025 | gurufocus.comCureVac’s Financial Resilience Amid Operational Challenges and Clinical Trial Uncertainties: A Hold Rating AnalysisApril 14, 2025 | tipranks.comCureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call TranscriptApril 12, 2025 | insidermonkey.comCureVac N.V. Earnings Call: Financial Strength Amid ChallengesApril 11, 2025 | tipranks.comQ4 2024 CureVac NV Earnings CallApril 11, 2025 | uk.finance.yahoo.comSee More Headlines CVAC Stock Analysis - Frequently Asked Questions How have CVAC shares performed this year? CureVac's stock was trading at $3.41 at the beginning of 2025. Since then, CVAC stock has increased by 4.4% and is now trading at $3.56. View the best growth stocks for 2025 here. How were CureVac's earnings last quarter? CureVac (NASDAQ:CVAC) posted its quarterly earnings results on Thursday, April, 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.01. The business earned $15.44 million during the quarter, compared to the consensus estimate of $6.40 million. CureVac had a trailing twelve-month return on equity of 21.98% and a net margin of 20.72%. Read the conference call transcript. When did CureVac IPO? CureVac (CVAC) raised $200 million in an IPO on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers. Who are CureVac's major shareholders? CureVac's top institutional shareholders include Ballentine Partners LLC (0.01%), Signaturefd LLC (0.01%) and Greenleaf Trust. How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA). Company Calendar Last Earnings4/10/2025Today5/04/2025Next Earnings (Estimated)5/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CVAC CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees880Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$16.00 Low Stock Price Target$12.00 Potential Upside/Downside+293.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.82 Trailing P/E Ratio6.47 Forward P/E Ratio4.94 P/E GrowthN/ANet Income$-281,580,000.00 Net Margins20.72% Pretax Margin27.11% Return on Equity21.98% Return on Assets15.72% Debt Debt-to-Equity Ratio0.05 Current Ratio6.20 Quick Ratio6.19 Sales & Book Value Annual Sales$535.18 million Price / Sales1.49 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book1.42Miscellaneous Outstanding Shares224,338,000Free Float219,067,000Market Cap$798.64 million OptionableOptionable Beta2.48 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CVAC) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.